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Abstract There are currently limited data regarding paediat-
ric Behçet’s disease (BD), particularly in the UK. We describe
the clinical spectrum, treatment and outcome of BD, and ex-
plore the relative sensitivities of the criteria for the diagnosis
of BD in a UK paediatric cohort. Single retrospective case
note review of children with a clinical diagnosis of BD pre-
senting between 1987 and 2012. Demographics, clinical fea-
tures, treatment and outcomes were recorded. The sensitivities
of the International Study Group (ISG) and International
Criteria for BD (ICBD) criteria were explored. BD disease
activity was calculated using the Behçet’s Disease Activity
Index (BDAI). Forty-six patients (22 male) were identified.
Median age of onset was 4.87 (0.04–15.71) years; median
time to diagnosis was 3.74 (0.25–13.48) years. Clinical fea-
tures were recurrent oral ulceration (97.8 %), recurrent genital
ulceration (73.9 %), gastrointestinal (58.7 %), musculoskele-
tal (47.83 %), cutaneous (23.9 %) involvement and uveitis
(2 %). Recurrent genital ulceration was more common in fe-
male patients (P=0.044). Thirty-seven patients (80.4 %) ful-
filled the ICBD criteria; only 12 patients (26.1 %) fulfilled the
ISG criteria. BDAI score at diagnosis was 7/20 (0–10/20) and
significantly decreased to 5/20 (0–9/20) (P<0.0001) at latest
follow-up. The commonest systemic treatment was colchicine
(76.1 %); anti-TNFα treatment was reserved for severe cases
(15.5 %). Paediatric BD in the UK may present very early in
life, sometimes with a family history, and with a low incidence
of ocular involvement. Diagnostic delay is common. The ma-
jority of our patients required systemic therapy; anti-TNFα
was reserved for severe cases and has largely superseded the
use of thalidomide.
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Introduction
Behçet’s disease (BD) [1] is a chronic multisystem vasculitis
characterized by recurrent oral and genital ulceration, uveitis,
cutaneous, articular, neurological and gastrointestinal involve-
ment [2–8]. There are currently no universally recognised pa-
thognomonic tests or biomarkers for BD disease activity, and
thus diagnosis and disease monitoring require astute clinical
acumen [9]. Although the usual onset of disease is between
the second and fourth decade, there has been an increased
awareness of BD during childhood [10–12]. Children account
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for 7.7–26.4 % of the reported prevalent cases of BD outside
the UK [1, 3]. In one UK study, only one paediatric BD case
was identified in a population of 1.1 million children [13].
Thus, due to the rarity of the condition and its non-specific
presentation, the diagnosis of BD is challenging for paediatri-
cians, and diagnostic delay of several years is common. This
may lead to irreversible complications such as blindness, neu-
rological injury and other end-organ damage.
There are several sets of criteria for the diagnosis and/or
classification of BD [9]; none have been validated in children.
The most widely used for adult onset disease are the
International Behçet’s Study Group (ISG) criteria
(Supplementary Table 1); these are considered to have subop-
timal sensitivity for the classification or diagnosis of BD in
adults, however [14]. Recently, International Criteria for
Behçet’s Disease (ICBD) have been validated in adults
(Supplementary Table 2) [7] with 94.8 % sensitivity and
90.5 % specificity. In comparison, the ISG criteria are 81 %
sensitive and 96 % specific for the diagnosis of BD [7]. It is
suggested therefore that the ICBD criteria should be used as
the gold standard [7, 9]. There are currently no data in relation
to the performance of the ICBD criteria in paediatric patients.
There is also a lack of evidence base for treatment of BD,
particularly in children [15]. Notably, the vast majority of
published paediatric series come from countries where BD is
prevalent; consequently, the clinical phenotype and burden of
disease is not well described for the UK-based paediatric pop-
ulation, and is likely to differ given established differences in
genetic background and environment.
The primary aim of this study was to describe the clinical
spectrum, therapy and outcome of children with BD present-
ing to a large tertiary paediatric referral centre based in the UK
and compare with other international paediatric series. A sec-
ondary aim was to explore the relative sensitivities of the ISG
and ICBD criteria for the diagnosis of BD in this paediatric
cohort.
Methods
Study population
We identified from our clinical database, all patients
(<18 years of age) with a clinical diagnosis of BD (based on
clinicians’ expert opinion as the gold standard, see statistics
section below) seen at Great Ormond Street Hospital in
London between January 1987 and December 2012. Ethical
approval was given by our Institution’s Research Ethics
Committee for a retrospective case note review; thus, no writ-
ten consent from patients was required. The demographic,
clinical, and laboratory characteristics recorded at diagnosis
were sex, age, ethnicity, organ involvement, erythrocyte sed-
imentation rate (ESR; reference range 0–10 mm/h) and serum
C-reactive protein (CRP; reference range 0–20 mg/L). We
tested the applicability of the ISG [2], and the ICBD criteria
[7] in our cohort. The BD Activity Index (BDAI) score [16]
(range 0–20, where 0 indicates no disease activity; full glos-
sary of terms available as a supplementary document) was
calculated retrospectively. The time from disease onset to di-
agnosis, number of relapses and relapse symptoms were re-
corded. Gender differences in presenting symptoms were ex-
plored. Disease and treatment-related morbidities were deter-
mined. Osteopenia was defined as a z score of body mass-
adjusted bone density more than two standard deviations be-
low the mean for age identified with a dual energy X-ray
absorptiometry (DEXA) scan. Growth standard deviation
scores (z scores) were calculated based on UK normative data
using a free downloadable Microsoft Excel add-on [17].
Presenting clinical features and demographics of this UK co-
hort were compared to other published paediatric series.
Statistical analyses
Continuous variables were summarised as median and range;
categorical variables were presented as percentages.
Parameters between groups were compared using Fisher’s ex-
act test. P values <0.05 were considered significant. Statistical
analysis was done with SPSS version 21. Estimates of sensi-
tivity for the ISG and ICBD criteria were calculated using the
formula: sensitivity=TP/(TP+FN); (true positive (TP); false-
negative (FN), using physician diagnosis of BD as gold stan-
dard for the purposes of this retrospective study). 95 % confi-
dence intervals for sensitivities were calculated. No estimates
of specificity of either tool were obtained since this study did
not include disease controls.
Results
Demographics and clinical characteristics
Forty-six patients were identified; 22 male (47.8 %). Eight
patients (17.0 %) had a family history suggestive of BD in a
first-degree relative. Forty-two patients (91.3 %) were
Caucasian; two from United Arab Emirates; one Saudi
Arabian; and one Palestinian. The median age of disease onset
was 4.87 (0.04–15.71) years; median time to diagnosis was
3.74 (0.25-13.48) years, and median length of follow-up 2.54
(0.2–13.4) years (Supplementary Table 3).
Presenting features
Clinical features present within the first 6 months of disease
onset were recurrent oral ulceration (OU; 82.6 %), recurrent
genital ulceration (GU; 17.4 %), gastrointestinal symptoms
(26.2 %), musculoskeletal symptoms (arthritis/arthralgia;
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21.7 %), fever (28.3 %), skin lesions (10.9 %) and ocular
involvement (2.2 %; Table 1).
Cumulative clinical features
Recurrent OU was present in 45/46 (97.8 %) patients over the
whole disease course. The median age of OU onset was 3.89
(0.04–15.71) years. Data on number of OU attacks per year
was available for 40 patients and ranged from 4 to 12 (median
6) episodes/year. Genital ulceration was present in 34/46 pa-
tients (73.9 %) and commonly occurred after the onset of OU
at the age of 10.5 (0.98–16) years with only 17.4 % children
having genital ulceration in the first 6 months since disease
onset. The scrotum was the most commonly affected area in
males (13/13); vulval ulceration was the commonest affected
genital site in females (19/21) followed by vaginal mucosal
ulceration (2/21).
Fever affected 14/46 (30.4 %). Skin manifestations docu-
mented in 11 patients (23.9 %) included pustular lesions in
3/11, skin ulceration in 2/11, erythema nodosum in 2/11, nec-
rotizing folliculitis in 2/11 and acneiform lesions in 2/11. A
pathergy test was performed in five patients; 3/5 patients (all
British Caucasian females) reported eruption of small pustules
at the venipuncture sites 2–3 days later.
All patients had yearly ophthalmology reviews as a mini-
mum. Ocular involvement was reported in only four patients
(8.7 %): two male patients had anterior uveitis and two female
patients had conjunctivitis, possibly unrelated to BD. For one
patient, anterior uveitis was the first presenting symptom of
BD. No patients had panuveitis or posterior uveitis.
Arthralgia was reported in 14 (30.4 %); arthritis in 10 pa-
tients (21.7 %) and myalgia in 4 cases (8.7 %).
Gastrointestinal involvement was present in 26 patients
(56.5 %): transient severe abdominal pain (attributed to BD
by the physician) was the most frequently reported finding
(n=12; 26.1 %), which regressed spontaneously or in re-
sponse to corticosteroids and required no further investigation.
Fourteen patients (30.4 %) had more serious gastroenterolog-
ical pathology including gastrointestinal haemorrhage
(melena or haematemesis) (n=2) and recurrent anal/perianal
ulcers in five patients (10.9 %). Gastrointestinal tract endos-
copy was performed in 10 children and showed gastritis in 3
patients, colonic ulcers in 2 patients, oesophagitis in one pa-
tient and oesophageal ulceration in another. The remaining
patients had a normal endoscopy.
Neurological involvement was documented in 13 patients
(28.3 %); 1 patient developed seizures and 11 patients report-
ed frequent (more than once a week) headaches. One patient
gradually developed neurogenic bladder dysfunction and re-
quired suprapubic catheter insertion. Brain computed tomog-
raphy scan and/or magnetic resonance imaging were done in
six patients, and no abnormality was found in four patients.
Sagittal sinus thrombosis was observed in the remaining two
patients (4.3 %); this was the initial manifestation of their
disease. Cerebral spinal fluid analysis was available for two
patients and was normal.
Urinary sediment abnormalities included mild proteinuria
(three cases; 6.5 %) and haematuria (two cases; 4.3 %). One
patient had persistent microscopic hematuria; renal ultrasound
was normal, and there was no evidence of biochemical distur-
bance to account for this.
Cardiac involvement was documented in one patient
(2.2 %) who developed a mild pericardial effusion. Vascular
complications were found in three patients (6.5 %): two with
sagittal sinus thrombosis (as mentioned above) and one devel-
oped thrombophlebitis of the lower leg.
Gender differences
Recurrent GU was significantly more common in females
(P=0.044); supplementary Table 3. There were no other sig-
nificant gender differences observed for any other data. No
data in relation to GU and onset of puberty were available.
Laboratory evaluation
HLA-B51 typing was performed in three cases; negative in
all. At diagnosis, ESR (measured in 42/46 patients) was 9mm/
h (range 1–122; 38 % had elevated ESR >10 mm/h); CRP
(measured in 38) was 5 mg/L (range 1–60; only one patient
had elevated CRP at presentation); white blood cell count was
6.92 × 1000 cells/mm3 (2.14–12.97); platelet count was
293.5 × 1000 cells/mm3 (179–570). Antinuclear antibodies
were detected in 9/46 patients (19.6 %). One patient was tran-
siently positive for proteinase 3 antineutrophil cytoplasmic
antibodies (32 U/mL; normal <10 U/mL).
Genetic testing for common autoinflammatory diseases
Genetic testing for autoinflammatory conditions became
available in 2004 at our institution. 8/46 patients who had
prominent fevers and/or systemic inflammation had testing
for monogenic autoinflammation: mevalonate kinase defi-
ciency (7/8), cryopyrin-associated periodic fever (4/8), famil-
ial Mediterranean fever (8/8) and NOD2 (1/8) mutations. All
testing was negative for the above conditions.
Performance of the ISG versus ICBD criteria
for the diagnosis of BD
Retrospectively, only 6/46 patients fulfilled ICBD criteria at
the first presentation, compared with 1/46 fulfilling the ISG
criteria. At the time of formal clinical diagnosis 37/46 patients
(80.4 %) fulfilled ICBD criteria compared with 8/46 patients
(17.4 %) who fulfilled ISG criteria. During follow-up, four
more patients presented more features thus fulfilling the ISG
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criteria. The sensitivities of both sets of diagnostic criteria at
diagnosis and last follow-up are presented in Table 2.
Treatment
Our general therapeutic approach to immunosuppression was
that of a ‘therapeutic ladder’, starting with topical corticoste-
roids, escalating sequentially to colchicine, systemic cortico-
steroids, followed by other drugs such as azathioprine, myco-
phenolate mofetil, thalidomide, or biologic therapy in cases of
inadequate control [15].
Treatments received are summarised in Table 3. Topical
therapies (received by all the patients) included singly or in
combination corticosteroid mouthwashes or 0.1 % triamcino-
lone oral paste for oral lesions; and 1 % hydrocortisone cream
for genital ulceration and other inflammatory cutaneous le-
sions. Forty-five patients (97.8 %) needed addition of system-
ic treatment a median of 4 months (0–28 months) from
diagnosis. For first line systemic therapy, 24 patients
(52.2 %) were treated with oral colchicine (dose ranging be-
tween 0.5 and 2 mg/day); 5 patients (10.9 %) received oral
thalidomide (dose ranging between 1 and 2 mg/kg once week-
ly to daily [18]; all presenting before 2001; and 5 patients
(10.9 %) with azathioprine (dose ranging between 1 and
3 mg/kg/day). Short-course oral prednisolone (dose 0.5–
1 mg/kg/day for 7 days) was prescribed for relapsing oro-
genital ulcers in six patients (13.0 %). Anti-tumour necrosis
factor alpha (TNFα) was used in seven patients (15.2 %);
adalimumab in five patients, infliximab in one patient and
etanercept in one patient, at 19 (3.3–109) months after disease
onset; 6/7 had severe gastrointestinal symptoms and one pa-
tient had relapsing genital ulcers refractory to other systemic
medications. The median BDAI score prior to anti-TNFαwas
8/20 (7–10); and significantly decreased to 5/20 (range 0–8) at
latest follow-up (median 40, range 2–76 months; P=0.0127.
Regarding the two patients with sagittal vein thrombosis, one
Table 1 Summary of the clinical
features present in first 6 months
from diagnosis, and over the
whole disease course in a cohort
46 children with Behçet’s disease
in a single UK paediatric
rheumatology tertiary centre
Number (%) with feature in
the first 6 months (N= 46)
Number (%) with feature in
whole disease course (N= 46)
Recurrent oral ulceration 38 (82.6) 45 (97.8)
Genital ulceration 8 (17.4) 34 (73.9)
Skin lesions 5 (10.9) 11 (23.9)
Pustular lesions 1 (2.2) 3 (6.5)
Skin ulceration 1 (2.2) 2 (4.3)
Erythema nodosum 1 (2.2) 2 (4.3)
Necrotizing folliculitis 1 (2.2) 2 (4.3)
Acneiform lesions 1 (2.2) 2 (4.3)
Pathergy* 0 3/5 (60)
Ocular lesions 1 (2.2) 4 (8.7)
Anterior uveitis 1 (2.2) 2 (4.3)
Conjunctivitis 0 2 (4.3)
Gastrointestinal manifestations 12 (26.1) 26 (56.5)
Abdominal pain 4 (8.7) 12 (26.1)
Gastrointestinal haemorrhage 1 (2.2) 2 (4.3)
Gastrointestinal ulceration 2 (4.3) 7 (15.2)
Anal/perianal ulceration 2 (4.3) 5 (10.9)
Recurrent diarrhoea 3 (6.5) 6 (13.0)
Fever 13 (28.3) 14 (30.4)
Arthritis 4 (8.7) 10 (21.7)
Neurological manifestations 5 (10.9) 13 (28.3)
Seizure 0 1 (2.2)
Frequent headache 5 (10.9) 11 (23.9)
Vascular complication 2 (4.3) 3 (6.5)
Sagittal sinus thrombosis 1 (2.2) 2 (4.3)
Thrombophlebitis 0 1 (2.2)
Serositis
Pericardial effusion 1 (2.2) 1 (2.2)
*Pathergy test was only performed in five patients, and was positive in 3/5
Clin Rheumatol
received warfarin for 6 months; the other only received low-
dose aspirin since the thrombosis had probably occurred years
previously as indicated by the presence of extensive venous
collaterals on imaging. This patient ultimately required a
ventriculoperitoneal shunt insertion due to intracranial hyper-
tension that failed to respond to acetazolamide.
Disease and treatment-related morbidities
Median BDAI at diagnosis was 7/20 (0–10) and significantly
decreased to 5 (0–9; P < 0.0001) at latest follow-up of
2.54 years (0.2–13.4 years). Significant corticosteroid-related
side effects included Cushing’s syndrome in 4/19 (21.1 %),
and osteopenia in 2/19 patients (10.5 %) where this was
assessed with DEXA scanning. Peripheral neuropathy was
documented in 6/13 patients (46.2 %) receiving thalidomide
therapy. Twenty-six patients had growth data available at the
last follow-up; median height Z score was −0.49 (−2.41–
2.51); median weight Z score was −0.1 (−2.33–2.74); and
median body mass index (BMI) Z score was 0.28 (−2.23–
2.37). No significant correlation between BDAI at diagnosis
or last follow-up and growth Z score was found. One patient
had a bone density Z score <−1.96 treated conservatively; no
fractures were documented. One patient had ongoing
neurogenic bladder symptoms at last review; and one afore-
mentioned patient had a VP shunt. Of note, no patient had
visual impairment; and no other permanent morbidities, or
deaths occurred.
Discussion
We describe the largest single-centre UK paediatric cohort of
BD which suggests differences compared with studies involv-
ing Asian or Turkish children (Table 4). In addition, for the
first time, we retrospectively examined the diagnostic sensi-
tivity of the ICBD criteria in children. Patients in our study
had early onset of disease at 4.87 years of age (median; range
0.04–15.71), and 17 % had a positive family history. The
clinical presentation was varied and broad. Table 4 summa-
rises the clinical phenotype of our UK-based paediatric cohort
compared to other paediatric series [8, 19–22]. We observed
less ocular involvement, and no posterior/panuveitis; less vas-
cular disease; and less cutaneous disease. Gastrointestinal and
neurological involvement was more frequent compared to
non-UK cohorts. We noted a significant diagnostic delay up
to 13.5 years. This is unfortunately common in children with
BD [19], due to the insidious nature of the disease and an
Table 2 Retrospective
application of the ICBD [7] and
ISG [2] diagnostic criteria:
sensitivity* of the criteria at
diagnosis and last follow-up
No. (%) of patients fulfilling
the criteria (N= 46)
Sensitivity (%; 95 %
confidence interval)
At diagnosis ICBD 37 (80.4) 80 (67–93)
ISG 8 (17.4) 17 (6.0–28)
At last follow-up ICBD 37 (80.4) 80 (67–93)
ISG 12 (26.1) 26 (13–39)
*Sensitivity = TP/(TP+FN); (true positive (TP); false-negative (FN), i.e. not fulfilling the criteria for a diagnosis
of BD, using physician diagnosis of BD as gold standard for the purposes of this retrospective study). ICBD
International Criteria for Behçet’s disease; ISG International Study Group
Table 3 Systemic treatment for
46 children with Behçet’s disease
in a single UK paediatric
rheumatology tertiary centre
Total patients receiving
treatment at any time (%)
First line systemic therapy
no. (%) of patients
Colchicine (0.5–2 mg/day) 35 (76.1) 24 (52.2)
Thalidomide 13 (28.3) 5 (10.9)
Oral prednisolone 20 (45.5) 8 (17.3)
Short coursea (0.5–1 mg/kg/day) 6 (13.0) 6 (13.0)
Continuousb (0.5–1 mg/kg/day) 14 (30.4) 2 (4.3)
Azathioprine 15 (32.6) 5 (10.9)
Sulfasalazine 3 (6.5) 1 (2.2)
Methotrexate 3 (6.5) 2 (4.3)
Adalimumab 5 (10.9) –
Infliximab 1 (2.2) –
Etanercept 1 (2.2) –
a Short course oral prednisolone = a course of continuous oral prednisolone for <28 days
b Continuous oral prednisolone = continuous oral prednisolone >28 days
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overall lack of awareness of BD. These differences could im-
pact on choice of immunomodulatory therapy used since.
Interestingly, only 8.7% of the children had ocular involve-
ment in our series and none had sight threatening disease with
posterior or panuveitis; this contrasts with the high frequency
of 33.9 % reported in an international study [21] and 42 % in
Israeli children [23]. We speculate whether this could arise
from genetic differences between our predominantly
Caucasian population and non-UK cohorts. We also noted
an increased frequency of genital ulceration in female patients
(Supplementary Table 3).
We demonstrated the limitations of the ISG diagnostic
criteria: only 17.4 % of our patients met these criteria at pre-
sentation to our centre. Similarly, in a previous multicentre
paediatric study of BD, only 42 % fulfilled the ISG criteria
as complete cases [21]; the authors proposed that age of pu-
berty should be included as a parameter for definite BD as
genital ulceration that usually starts after puberty; we were
unable to assess this in our retrospective study since pubertal
status was not assessed systematically. We demonstrated
much higher sensitivity (80.4 %, 95 % CI 67–93 %;
Table 2) of the ICBD diagnostic criteria compared to the
ISG criteria at the time of clinical diagnosis. We did not study
the specificity of the ICBD criteria, as this would require a
disease control population comprising patients with important
mimics of BD, such as periodic fever, aphthous stomatitis,
pharyngitis and adenitis (PFAPA) amongst others
(Supplementary Table 4). Whilst many experienced clinicians
may not rely on such criteria for the diagnosis of BD in routine
practice, such criteria are important for epidemiological and
clinical studies. For instance, in the UK, a multi-centre collab-
orative study from the British Paediatric Surveillance Unit
(BPSU) regarding the epidemiology and clinical phenotype
of paediatric BD is now underway, and is using the ICBD
criteria to define BD cases.
We explored the utility of the prototypic BDAI score for the
first time in children in an attempt to systematically assess
disease activity and response to therapy. We emphasise how-
ever, that retrospective scoring may be unreliable, and is there-
fore a limitation of our study. That said, this scoring system at
least provides a systematic way of collecting such data retro-
spectively. BDAI scores significantly improved after treat-
ment, and therefore could be an important tool for clinicians
to monitor the BD disease course and should be now prospec-
tively validated in paediatric patients.
Patients in our study were treated with a variety of thera-
peutic agents. The majority (93.5 %) of our patients required
systemic therapy. Thalidomide-induced peripheral neuropathy
occurred in 6/13 patients who received this; thus, less toxic
therapeutic agents should be considered first. We used anti-
TNFα treatment in severe/refractory cases (15.5 % of pa-
tients), an approach reported to be effective in adult studies
[24]. More recently, IL-1 blockade has been highlighted asTa
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potentially useful [25], but we have not yet used this approach,
nor interferon-α [26] for BD in children at our institution.
Overall, the prognosis for BD in our series was good. No
child died; we did not observe any fractures; median final Z
score for height, weight and bodymass index at last follow-up
was −0.49, −0.1 and 0.28, respectively. Despite these encour-
aging hard endpoints, the fact that 87 % of patients were still
on treatment, emphasises that BD is a lifelong chronic disease.
Our study was limited by all the confounding factors asso-
ciated with any single-centre retrospective series of patients
with a rare disease. There is a possibility that referral bias
resulted in us receiving the most severe cases. Pathergy and
HLA B51 testing was not routinely performed. Importantly,
we were unable to assess quality of life and any changes
associated with treatment, an area of concern for patients with
BD [27], and for understanding the heath economics of BD
and its treatment in the young.
In summary, we present the largest UK-based single-centre
series of children with BD, showing a distinctive clinical phe-
notype in this population. We observed less ocular involve-
ment, less vascular disease, and less cutaneous disease.
Gastrointestinal and neurological involvement was more fre-
quent compared to non-UK cohorts. Colchicine appears to be
an effective treatment; anti-TNFα treatment was used for re-
fractory cases and has now largely superseded the use of tha-
lidomide in our institution. Further prospective multicentre
national studies using paediatric research networks such as
the BPSU are currently underway, and will further character-
ise the epidemiology and clinical phenotype of BD in UK
children, and could provide prospective data on whether any
phenotypic differences influence choice of therapy. Lastly,
whether these observed differences persist into adulthood re-
mains to be determined, and will require long-term cohort
studies. In the meantime, studies comparing children and
adults with BD in the UK could help explore whether there
are true differences between childhood and adult onset BD in
the UK.
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